[Clinical and blood rheologic effects of ticlid in patients with cerebrovascular diseases].
Clinical efficacy of tiklid in a dose 500 mg/day and its action on platelet vascular hemostasis were evaluated in 24 patients with cerebrovascular diseases. A 15-day tiklid course promoted a regress in some subjective symptoms (headache, vertigo, walking instability, photopsias, etc.), the objective neurological status being unchanged. Tiklid had a positive influence on some rheological parameters and platelet vascular hemostasis. ADP-induced platelet aggregation, blood fibrinogen levels got reduced. The platelets sensitivity to antiaggregation agent PgI2 in vitro arose. Antiaggregation potential of the vascular wall returned to normal in 33% of patients with initially low or inverse response.
Suslina
Z A
ZA
Ionova
V G
VG
Nikitenko
N Iu
NIu
Maksimova
M Iu
MIu
D000328:Adult; D001780:Blood Coagulation Tests; D001809:Blood Viscosity / Q000187:drug effects*; D002561:Cerebrovascular Disorders / Q000097:blood / Q000188:drug therapy*; D002908:Chronic Disease; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D013988:Ticlopidine / Q000627:therapeutic use*
D013988:Ticlopidine
Klinicheskie i gemoreologicheskie éffekty tiklida u bol'nykh tserebrovaskuliarnymi zabolevaniiami.